Vanguard Reports 0 Shares in Emergent BioSolutions
Emergent BioSolutions Schedule 13G/A shows The Vanguard Group reports 0 shares beneficially owned of Common Stock as of 03/13/2026, representing 0% of the class.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Emergent BioSolutions Schedule 13G/A shows The Vanguard Group reports 0 shares beneficially owned of Common Stock as of 03/13/2026, representing 0% of the class. The filing cites an internal realignment and reliance on SEC Release No. 34-39538 that led certain Vanguard subsidiaries to report holdings separately. The form is signed on 03/26/2026 by Ashley Grim, Head of Global Fund Administration.
Insights
Vanguard disaggregated holdings; reports no beneficial ownership in EBS after internal reorganization.
The filing states 0 shares beneficially owned and 0% of the class as of 03/13/2026, citing SEC Release No. 34-39538 for disaggregation of subsidiary reporting. This is an administrative ownership update tied to internal structure changes, not a market transaction.
Cash-flow treatment and trading activity are not described in the excerpt; subsequent filings from Vanguard or subsidiaries may show holdings if they hold shares directly.
AI-generated analysis. How Rhea-AI works. Not financial advice.